BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

Phase 4

Completed

Conditions: Rhinitis, Allergic

Interventions: Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)
Drug: Placebo tablet
Drug: Fluticasone Propionate
Drug: Placebo spray

First Posted Date: 2018-02-23

Last Posted Date: 2019-12-20

Lead Sponsor: Bayer

Target Recruit Count: 82

Registration Number: NCT03443843

Locations: 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada

In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control

Not Applicable

Completed

Conditions: Atopic Dermatitis

Interventions: Device: Modified Diprobase formulation (BAY987534)

First Posted Date: 2018-02-22

Last Posted Date: 2020-07-24

Lead Sponsor: Bayer

Target Recruit Count: 40

Registration Number: NCT03441568

Locations: 🇬🇧
West Timperley Medical Centre, Altrincham, United Kingdom

BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect

Phase 1

Completed

Conditions: Endometriosis

Interventions: Drug: Placebo
Drug: BAY2328065

First Posted Date: 2018-02-09

Last Posted Date: 2024-02-29

Lead Sponsor: Bayer

Target Recruit Count: 72

Registration Number: NCT03427788

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

Phase 1

Completed

Conditions: Clinical Pharmacology

Interventions: Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)

First Posted Date: 2018-02-06

Last Posted Date: 2019-03-20

Lead Sponsor: Bayer

Target Recruit Count: 60

Registration Number: NCT03424135

Locations: 🇺🇸
ICON Development Solutions, LLC, San Antonio, Texas, United States

Multi-academic Center Study of Xofigo Patients

Completed

Conditions: Prostate Cancer, Castration Resistant

Interventions: Drug: Xofigo
Drug: Taxotere
Drug: Jevtana

First Posted Date: 2018-02-05

Last Posted Date: 2020-10-22

Lead Sponsor: Bayer

Target Recruit Count: 150

Registration Number: NCT03419442

Locations: 🇺🇸
Bayer US, Whippany, New Jersey, United States

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects

Phase 3

Completed

Conditions: Anemia
Renal Insufficiency, Chronic

Interventions: Drug: Molidustat (BAY85-3934)

First Posted Date: 2018-02-01

Last Posted Date: 2021-01-29

Lead Sponsor: Bayer

Target Recruit Count: 51

Registration Number: NCT03418168

Locations: 🇯🇵
Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
🇯🇵
Asahi University Hospital, Gifu, Japan

and more 24 locations

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

Completed

Conditions: Macular Degeneration

Interventions: Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

First Posted Date: 2018-01-26

Last Posted Date: 2019-12-05

Lead Sponsor: Bayer

Target Recruit Count: 116

Registration Number: NCT03411941

Locations: 🇪🇸
Many locations, Multiple Locations, Spain

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

Phase 2

Completed

Conditions: Diabetic Kidney Disease

Interventions: Drug: Fulacimstat (BAY1142524)
Drug: Placebo

First Posted Date: 2018-01-26

Last Posted Date: 2022-03-03

Lead Sponsor: Bayer

Target Recruit Count: 152

Registration Number: NCT03412006

Locations: 🇧🇬
Med. Center Equita, Varna, Bulgaria
🇫🇮
TAYS TKI Keskus Tutkimusvastaanotto, Tampere, Finland
🇮🇱
The Nazareth Trust Hospital EMMS, Nazareth, Israel

and more 24 locations

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

Phase 1

Completed

Conditions: Uterine Fibroids
Endometriosis

Interventions: Drug: Vilaprisan (BAY1002670)

First Posted Date: 2018-01-26

Last Posted Date: 2019-12-03

Lead Sponsor: Bayer

Target Recruit Count: 26

Registration Number: NCT03411980

Locations: 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Transitional Cell

Interventions: Drug: Rogaratinib (BAY1163877)
Drug: Chemotherapy

First Posted Date: 2018-01-25

Last Posted Date: 2022-09-28

Lead Sponsor: Bayer

Target Recruit Count: 175

Registration Number: NCT03410693

Locations: 🇺🇸
Summit Cancer Center, Spokane, Washington, United States
🇨🇦
Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada
🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

and more 158 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy